Long-term Complete Response in a Patient with Disseminated Pulmonary Pleomorphic Carcinoma Induced by Cisplatin and Gemcitabine
-
- Tamiya Akihiro
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Asami Kazuhiro
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Shimizu Shigeki
- Department of Clinical Laboratory, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Matsumura Akihide
- Department of Surgery, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Isa Shun-Ichi
- Department of Clinical Research, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Okishio Kyoichi
- Department of Clinical Research, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Kitaichi Masanori
- Department of Clinical Laboratory, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Atagi Shinji
- Department of Clinical Research, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Takada Minoru
- Department of Internal Medicine, Koyo Hospital, Japan
-
- Kawaguchi Tomoya
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan
-
- Kubo Akihito
- Department of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Japan
Search this article
Abstract
A 47-year-old man was referred to our department due to multiple metastases in the lungs and liver with pleural dissemination six weeks after undergoing curative surgery for lung pleomorphic carcinoma. He received two regimens of chemotherapy, both of which resulted in disease progression. Considering his good general condition, he was treated with cisplatin plus gemcitabine (GP). The metastatic lesions exhibited a complete response after six courses of GP, and the patient has remained free from recurrence for over six years. An immunohistochemical analysis revealed that the tumor was highly expressive of gemcitabine transporter human equilibrative nucleoside transporter 1, thus suggesting a high sensitivity to gemcitabine.<br>
Journal
-
- Internal Medicine
-
Internal Medicine 53 (22), 2625-2628, 2014
The Japanese Society of Internal Medicine